米国企業
Bionano Genomics, Inc.

Bionano Genomics, Inc.BNGO

時価総額

PER

	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Cash and cash equivalents	17	17	38	25	5	18
Investments	-	-	-	226	108	49
Accounts receivable, net	5	6	3	5	7	9
Inventory	1	3	3	12	30	-
Inventory	-	-	-	-	-	23
Prepaid expenses and other current assets	919,500	1	2	4	7	6
Total current assets	23	28	47	272	157	140
Restricted investments	-	-	-	-	-	35
Total current assets	23	28	47	272	157	140
Restricted cash	-	-	-	-	0	0
Property and equipment, net	2	2	5	10	18	23
Operating lease right-of-use assets	-	-	-	7	7	6
Finance lease right-of-use assets	-	-	-	4	4	4
Intangible assets, net	-	-	1	27	41	34
Goodwill	-	-	7	56	77	-
Other long-term assets	-	-	102,640	1	2	7
Total assets	25	30	60	377	308	214
Accounts payable	1	3	3	10	13	10
Accrued expenses	3	3	6	10	11	8
Contract liabilities	270,998	357,492	415,504	1	1	-
Contract liabilities	-	-	-	-	-	1
Operating lease liability	-	-	-	1	2	2
Finance lease liability	-	-	-	0	0	0
Contingent consideration	-	-	-	-	9	-
Total current liabilities	5	26	9	22	36	100
Purchase option liability (at fair value)	-	-	-	-	-	9
Convertible notes payable (at fair value)	-	-	-	-	-	70
Total current liabilities	5	26	9	22	36	100
Operating Lease, Liability, Noncurrent	-	-	-	5	6	4
Finance Lease, Liability, Noncurrent	-	-	-	4	4	4
Contingent consideration, net of current portion	-	-	-	-	13	11
Deferred Revenue, Noncurrent	304,467	182,648	97,875	0	0	-
Long-term contract liabilities	-	-	-	-	-	0
Total liabilities	15	27	25	40	58	118
Preferred Stock, Value, Issued	-	-	-	-	-	-
Common Stock, Value, Issued	1,004	3,427	18,995	0	0	0
Additional paid-in capital	83	106	179	554	599	677
Accumulated deficit	-72,762,428	-102,577,498	-143,683,849	-216	-349	-581
Accumulated other comprehensive income (loss)	-	-	-	-1	-1	0
Total stockholders’ equity	10	4	35	337	249	96
Total liabilities and stockholders’ equity	25	30	60	377	308	214